Clinical Trial Update: Phase I/II Study of PLB1004 Combined With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation-positive [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II trial evaluating PLB1004 in combination with platinum-based chemotherapy in EGFR mutation-positive non-small cell lung cancer; the study is currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• PLB1004

Snippet

Sponsor: Avistone Pharmaceutical（Ningbo）Co., LTD. | Conditions: NSCLC (Non-small Cell Lung Cancer) | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING